LINC's Core Technology
The scientists at the Research and Education Institute at Harbor/UCLA
(REI) have demonstrated that PTHrP can modulate lung fibrosis in in
vitro and in vivo laboratory models. In addition, LINC’s data suggests
that pathways down-stream of PTHrP hormone system (the PPAR-gamma
system) are an integral part of the fibrosis cascade, providing several new
targets for therapeutic intervention.
Based on the discoveries of the LINC’s scientific founders, the company
intends to develop its technology in two complimentary product lines,
including a PTHrP-based diagnostic product to accurately monitor the
formation of pulmonary fibrosis, and therapeutic drugs based on PTHrP
analogs (and PPAR agonists/antagonists) to inhibit fibrosis in lung tissues.
Advantages of the Technology
Advantages of the LINC technology include providing a new diagnostic
capability to monitor early signs of lung damage associated with
mechanical ventilation in neonates suffering from bronchopulmonary
dysplasia, as well as in adults suffering from fibrotic lung disease. This
diagnostic will also provide an important new tool which will allow health
care providers to adjust ventilation systems to minimize undue stress on
the lungs.
In addition, LINC will provide an effective therapeutic regimen for the
treatment of progressive fibrotic lung disease that is currently not
available.
|
